This website is intended for healthcare professionals only

Trending Topic

Close-up of a person rubbing their temple, depicting persistent headache pain
13 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Migraines profoundly impact well-being, especially in children and adolescents. From 1990 to 2021, global pediatric migraine disability has increased, with particular vulnerability in females and adolescents aged 15–19.1 A 2023 meta-analysis found the prevalence of primary headache diagnosis in individuals aged 8–18 years to be 62%.2 The prevalence of a migraine diagnosis was 11%; 8% […]

Roger McIntyre – Psilocybin-based Therapies in Mood Disorders

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jul 21st 2020

TouchNEUROLOGY caught up with Roger McIntyre (University Toronto, Ontario, Canada) to discuss psychedelics, and in particular psilocybin-based therapies, and their potential in the treatment of mood disorders.

Questions

1. Please could you give us a brief overview of psilocybin and its action on serotonergic (5-HT) pathways? (0:04)

2. Which conditions are most likely to benefit from psilocybin therapy? (0:48)

3. What are the major challenges in bringing psilocybin-based products to the market? (1:57)

4. Could you tell us a little about the products you are working with and the current research activities? (3:18)

5. What will be the next steps in the development of psilocybin-based therapies? (4:38)

Speaker Disclosure: Roger McIntyre has acted as a consultant and/or received research support from Lundbeck, Janssen, Shire, Purdue, Pfizer, Otsuka, Allergan, Takeda, Neurocrine, Sunovion, Minerva, Intra-Cellular Pharmaceuticals, Stanley Medical Research Institute, and CIHR/GACD/National Natural Science Foundation of China. He is CEO of Champignon, which acquired the Canadian Rapid Treatment Centre of Excellence.

Support: Interview and filming supported by Touch Medical Media.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup